Scott Stevens "Approaches to VTE risk-stratification for medically ill hospitalized patients"
Scott M. Stevens, M.D., F.A.C.P., F.C.C.P. is the founder and Co-Director of the Thrombosis Clinic at Intermountain Medical Center. This service was established in 2004 and is one of the few clinical services in the state of Utah dedicated to the management of patients with Venous Thrombosis. Dr. Stevens and the Thrombosis Clinic team provide evaluation and management of complex thrombosis cases in both the outpatient and inpatient settings.
Dr. Stevens co-directs the Thrombosis Research Group at Intermountain Medical Center. He has served as principle investigator for numerous clinical trials, and has more than 150 publications in the field of thrombosis and anticoagulation.
Dr. Stevens has served on the steering committees for the National Institutes of Health-sponsored COAG and GIFT Trials, and the Canadian Institutes of Health Research’s DODS clinical trials. He also served as a panelist for the Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines and the Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report (the most cited guidelines in the field of thrombosis). He also served as the lead author for the guidance for the evaluation and treatment of hereditary and acquired thrombophilia section of the 2016 Clinical Guidance from the Anticoagulation Forum. He has served as a reviewer for the National Heart Lung and Blood Institute and the National Institute of Neurological Disorders and Stroke.
Gregory Piazza "Strategies to reduce hospital-acquired VTE for medically ill patients"
Dr. Woller is Co-Director of the Thrombosis Program at the Intermountain Medical Center, Professor of Medicine in the University of Utah School of Medicine, served as an Expert Panelist for the 10th edition of the American College of Chest Physicians Guideline VTE treatment guidelines, has a special interest in the prevention of hospital-associated venous thromboembolism (HA-VTE).
Supported by an unrestricted educational grant from: Bayer
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
The ISTH webinar series will provide high quality and state of the art education to practitioners around the world. Throughout the course of the year, the series will provide both clinical and basic science education in the areas of Thrombosis and Anticoagulation; Platelets and Vascular Biology; Coagulation and Bleeding Disorders.
- Be able to articulate several evidence-based strategies to predict the risk of hospital-acquired VTE in medical patients.
- Be able to utilize a risk assessment method to inform use of pharmacologic prophylaxis against VTE in hospitalized medical patients.
- Participants will learn about thromboprophylaxis for medically ill patients at risk for hospital-acquired VTE.
- Participants will learn about electronic health record based techniques to assess VTE risk and prevention practices
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:
|Geoffrey Barnes, MD, MSc||BMS/Pfizer, NHLBI, Blue Cross Blue Shield of Michigan, Portola Janssen||Research Investigator, Consultant|
|Meera Chitlur, MD||Bayer, Genentech, Novo nardisk, Baxter||Advisory Board, Consultant, Speaker|
|Gregory Piazza||BMS, Daiichi Sankyo, Portola, Janssen, Pfizer, Bayer||Research, Scientific Advisory|
|Scott Stevens, MD||Bristol-Meyer Squibb||IAR Co-Investigator|
|Scott Woller, MD||BMS||Investigator|